Emedgene

Company Overview

Snapshot

Founded in April 2015 by Einat Metzer, Shay Tzur, and Niv Mizrahi, Emedgene operated with 11–50 employees. The company raised a total of $6.02 million across three funding rounds from four investors, with OTV leading one of the rounds. Emedgene was acquired by Illumina in December 2021.

Business overview

Emedgene is a genomics intelligence platform that leverages natural language processing and machine learning to interpret genetic publications and identify pathogenic variants. Its technology aims to streamline clinical decision-making for geneticists and clinicians, enabling personalized patient care. The platform serves clinical laboratories and research organizations, enhancing dry lab efficiency, reducing interpretation time, and accelerating genomic-driven discovery. Emedgene operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Medical Decision Support, utilizing AI, machine learning, and natural language processing for genetic analysis.

Strategic signal

In December 2020, Emedgene collaborated with Illumina to scale the interpretation of genomic data for rare diseases, a strategic move that foreshadowed its acquisition by Illumina in December 2021. This collaboration highlighted Emedgene's technological validation and its potential to integrate with major players in the genomics industry, signaling strong market alignment and an attractive exit opportunity for investors.

Company Intelligence Q&A

What was a significant corporate milestone for Emedgene?

Emedgene was acquired by Illumina in December 2021, marking a key exit for the company and integrating its AI-based genomic interpretation platform into a leading DNA sequencing and array-based technologies provider.

When did Emedgene last raise a funding round?

Emedgene secured a funding round in February 2019, with OTV as a lead investor, alongside Mindset Ventures and RIO Ventures Holdings.

What was Emedgene's collaboration with Illumina?

In December 2020, Emedgene collaborated with Illumina to enhance the interpretation of genomic data, particularly for rare diseases. This partnership aimed to scale the application of Emedgene's AI technology within Illumina's ecosystem.

What was Emedgene's involvement with the Rare Genomics Institute?

In February 2020, Emedgene donated appraisals for undiagnosed rare disease patients to the Rare Genomics Institute and other organizations, demonstrating its commitment to supporting rare disease diagnosis and research.

Did Emedgene receive any grants?

In October 2018, Emedgene received a grant from the Israel Innovation Authority, supporting its continued development in genomic intelligence.